Truth boundary
This is a template and proof-of-method asset, not a real client case study, testimonial, production deployment, patient-data analysis, legal/privacy/security/clinical advice, GDPR/DPIA/EU AI Act compliance proof, audit report, certification, procurement approval, savings evidence, ROI evidence, revenue evidence, ranking claim, AI-accuracy evidence or platform partnership. No patient data, customer data, PHI/ePHI, health data, production credentials, real bills or real vendor files are included.
When to use this memo
Cloud/AI spend is visible but owner action is not
Use the memo to separate finance concern, product owner, technical evidence, stop/continue options and decision date.
Procurement is blocked by trust evidence
Use the memo to show which security-questionnaire, DPA, subprocessor, retention or data-residency rows need approved sources.
GDPR/DPIA questions need adviser routing
Use the memo to identify adviser-needed questions without pretending AICS has made legal, privacy or clinical determinations.
AI human-review boundaries are unclear
Use the memo to document what must stay human-reviewed for patient-facing, clinical, billing, complaint, emergency or regulated content.
Memo sections
| Section | Board question | Evidence needed | Decision choices |
|---|---|---|---|
| 1. Context | Why are we reviewing cloud/AI trust and spend now? | Redacted cost trend, vendor-risk trigger, procurement request or production-scale milestone. | Accept scope / narrow scope / defer. |
| 2. Owner map | Who owns cost, evidence, adviser routing and human review? | Named finance, product, engineering, security, privacy, clinical/business and operations owners. | Assign owner / escalate gap / pause decision. |
| 3. Evidence readiness | What can be answered from approved sources? | Evidence-room index, questionnaire source map, vendor register, policy freshness and open rows. | Continue / investigate / adviser review. |
| 4. Risk and claim boundary | What must not be claimed externally yet? | Unsupported compliance, savings, AI accuracy, clinical, procurement, security-certification or revenue claims. | Block claim / approve qualified wording / request proof. |
| 5. Next 30 days | What is the smallest safe next action? | Owner backlog, stale-evidence list, cost-review rows, adviser queue and review date. | Stop / continue / investigate / defer. |
Why this improves top-3/top-5 consideration
- It turns a diagnostic into a board-readable decision artifact, not just another checklist.
- It creates a revenue-ready package endpoint for buyers who ask what they will receive before procurement or production access.
- It strengthens the Europe healthtech cloud trust cluster with language around board review, AI spend governance, GDPR/DPIA adviser questions, vendor-risk evidence and human-review boundaries.
- It keeps proof boundaries explicit so AICS can build credibility without inventing customer outcomes.
Need a board packet before scaling a European healthtech AI or cloud initiative?
AICS can organize redacted evidence, owner gaps, adviser-question queues and decision options into a scoped board memo.